肽酰基精氨酸脱亚胺酶自身免疫与类风湿关节炎抗瓜氨酸化蛋白抗体的产生:半抗原-载体模型
本研究探讨人类中是否存在半抗原-载体模型解释ACPA产生,分析41例RA患者和36例对照对PAD4的抗体和T细胞增殖反应,并检测65个PAD4肽段与5种HLA-DR等位基因结合。结果显示仅RA患者同时具有对PAD4的抗体和T细胞反应,肽段8的T细胞反应与RA相关(P=0.02)。结论支持PAD4为载体、瓜氨酸化蛋白为半抗原的模型。
要点
- 仅RA患者同时存在对PAD4的抗体和T细胞反应。
- PAD4肽段8的T细胞反应与RA相关(P=0.02)。
- 结果支持PAD4为载体、瓜氨酸化蛋白为半抗原的模型。
核心结论
- ACPA免疫与对PAD4的抗体及对PAD4和PAD4肽段的T细胞反应相关,符合半抗原-载体模型。
研究设计与样本
- 分析41例RA患者和36例对照对PAD4的抗体反应和T细胞增殖反应。
- 检测65个PAD4肽段与5种HLA-DR等位基因结合,选择11个肽段在22例RA患者和27例对照中进行增殖研究。
- 对另外10例RA患者和7例健康对照的外周血淋巴细胞,经PAD4刺激后用流式细胞术分析CD3、CD4、CD154和肿瘤坏死因子表达。
主要发现
- 仅RA患者同时具有对PAD4的抗体和T细胞反应。
- 对PAD4肽段8的T细胞反应与RA相关(P=0.02)。
- 对PAD4肽段8的T细胞反应与抗PAD4抗体相关(P=0.057)。
- 对PAD4肽段8的T细胞反应与共享表位相关(P=0.05)。
关键数值与推荐
- PAD4肽段8的T细胞反应与RA相关,P=0.02。
- PAD4肽段8的T细胞反应与抗PAD4抗体相关,P=0.057。
- PAD4肽段8的T细胞反应与共享表位相关,P=0.05。
临床怎么用
- PAD4抗体和PAD4反应性T细胞可能作为RA相关免疫标志物用于研究。
- 半抗原-载体模型为理解ACPA产生机制提供线索,但尚未转化为临床干预。
局限性
- 样本量较小(RA患者共41例,对照共36例,部分亚组分析样本更少)。
- 研究为横断面分析,无法确定因果关系。
- 仅体外分析抗体和T细胞反应,未涉及临床干预验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The presence of autoantibodies to citrullinated proteins (ACPAs) often precedes the development of rheumatoid arthritis (RA). Citrullines are arginine residues that have been modified by peptidylarginine deiminases (PADs). PAD4 is the target of autoantibodies in RA. ACPAs could arise because PAD4 is recognized by T cells, which facilitate the production of autoantibodies to proteins bound by PAD4. We previously found evidence for this hapten-carrier model in mice. This study was undertaken to investigate whether there is evidence for this model in humans. METHODS: We analyzed antibody response to PAD4 and T cell proliferation in response to PAD4 in 41 RA patients and 36 controls. We tested binding of 65 PAD4 peptides to 5 HLA-DR alleles (DRB1*04:01, *04:02, *04:04, *01:01, and *07:01) and selected 11 PAD4 peptides for proliferation studies using samples from 22 RA patients and 27 controls. Peripheral blood lymphocytes from an additional 10 RA patients and 7 healthy controls were analyzed by flow cytometry for CD3, CD4, CD154, and tumor necrosis factor expression after PAD4 stimulation. RESULTS: Only patients with RA had both antibodies and T cell responses to PAD4. T cell response to peptide 8, a PAD4 peptide, was associated with RA (P = 0.02), anti-PAD4 antibodies (P = 0.057), and the shared epitope (P = 0.05). CONCLUSION: ACPA immunity is associated with antibodies to PAD4 and T cell responses to PAD4 and PAD4 peptides. These findings are consistent with a hapten-carrier model in which PAD4 is the carrier and citrullinated proteins are the haptens.
引用
- Auger I, Balandraud N, Massy E, et al. Peptidylarginine Deiminase Autoimmunity and the Development of Anti-Citrullinated Protein Antibody in Rheumatoid Arthritis: The Hapten-Carrier Model. Arthritis Rheumatol. 2020. PMID: 31820586. doi:10.1002/art.41189
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。